Axial mitochondrial myopathy in a patient with rapidly progressive adult-onset scoliosis
© Hiniker et al.; licensee BioMed Central Ltd. 2014
Received: 15 August 2014
Accepted: 4 September 2014
Published: 16 September 2014
Axial myopathy can be the underlying cause of rapidly progressive adult-onset scoliosis; however, the pathogenesis of this disorder remains poorly understood. Here we present a case of a 69-year old woman with a family history of scoliosis affecting both her mother and her son, who over 4 years developed rapidly progressive scoliosis. The patient had a history of stable scoliosis since adolescence that worsened significantly at age 65, leading to low back pain and radiculopathy. Paraspinal muscle biopsy showed morphologic evidence of a mitochondrial myopathy. Diagnostic deficiencies of electron transport chain enzymes were not detected using standard bioassays, but mitochondrial immunofluorescence demonstrated many muscle fibers totally or partially deficient for complexes I, III, IV-I, and IV-IV. Massively parallel sequencing of paraspinal muscle mtDNA detected multiple deletions as well as a 40.9% heteroplasmic novel m.12293G > A (MT-TL2) variant, which changes a G:C pairing to an A:C mispairing in the anticodon stem of tRNA LeuCUN. Interestingly, these mitochondrial abnormalities were not detected in the blood of either the patient or her son, suggesting that the patient’s rapidly progressive late onset scoliosis was due to the acquired paraspinal mitochondrial myopathy; the cause of non-progressive scoliosis in the other two family members currently remains unexplained. Notably, this case illustrates that isolated mitochondrial myopathy can underlie rapidly-progressive adult-onset scoliosis and should be considered in the differential diagnosis of the primary axial myopathy.
While adult scoliosis is a common disorder of the spine that often follows adolescent deformity, rapid progression of scoliosis with decompensation of posture occurs only rarely in the adult. Rapidly progressive adult-onset scoliosis is a debilitating and frequently painful condition that is poorly understood and typically considered idiopathic. One particularly well-known manifestation of adult-onset scoliosis is camptocormia or “bent-spine syndrome,” in which the patient’s spine is involuntarily flexed when standing or sitting . Until recently, little was known about the heritable and acquired factors leading to camptocormia, aside from an unclear but reproducible relationship to Parkinson’s disease –. However, recent work has demonstrated that camptocormia can be due to a localized axial myopathy leading to spinal instability .
While axial myopathies can be secondary to other neuromuscular disorders, in some cases they appear to arise de novo and are designated primary axial myopathies. While etiologically heterogeneous, this group of conditions is clinically characterized by progressive paraspinal muscle weakness, myogenic pattern on EMG, and normal to mildly elevated creatinine kinase (CK) levels. Pathologically, affected paraspinal muscles typically show chronic myopathic changes reminiscent of muscular dystrophy (fiber size variation, fatty infiltration, and fibrosis ). Interestingly, mitochondrial changes (ragged red and cytochrome c oxidase (COX)-negative fibers) have also been observed in primary axial myopathies ,, but are generally thought to represent non-specific age-related mitochondrial pathology. However, a recent illustrative report demonstrated that heritable mitochondrial DNA (mtDNA) mutations can also cause an axial myopathy : a familial late-onset axial myopathy due to mutation in the mitochondrial tRNA Phe gene was demonstrated in two elderly sisters with a history of encephalopathy and ataxia.
Here, we report a case of rapidly progressive adult-onset scoliosis due to late-onset axial myopathy associated with multiple somatic mtDNA abnormalities but without chronic myopathic features typically observed in primary axial myopathies. This case demonstrates that adult spinal deformity may be secondary to a previously undiagnosed neuromuscular pathology and that primary axial myopathy can be due to an apparently isolated mitochondrial myopathy.
Materials and methods
Biopsy of T8 paraspinal muscle was obtained intraoperatively during stage one of the two-stage spinal fusion. The flash-frozen muscle tissue was evaluated using a standard panel of muscle stains (hematoxylin and eosin [H&E]; modified trichrome; ATPase, pH = 9.4; NADH reductase; SDH; and COX). Light microscopy images were acquired with a DP72 digital camera on a BX41 bright-field light microscope using cellSens Entry 1.4 software (all by Olympus Corp.). For electron microscopy, ultrathin (80 nm) sections of the glutaraldehyde-fixed, Epon-embedded tissue were stained with 2% uranyl acetate. Sections were examined in a Tecnai G212 transmission electron microscope at 80 kV, with images obtained with a Hammamatsu camera model Orca HR.
Standard biochemical assays for enzyme activities of the electron transport chain were performed in duplicate on fresh frozen tissue at 30°C, according to previously published methods ,. The activities of complex I (NADH: ferricyanide dehydrogenase), complex II (succinate dehydrogenase), complex I + III (NADH: cytochrome C oxidase), complex II + III (succinate:cytochrome c reductase), and complex IV (cytochrome c oxidase) were measured using different electron acceptors/donors. Complex I was followed using the oxidation of NADH at 340 nm. Complex II activity was measured via the reduction of 2,6-dichloroindophenol (DCIP) at 600 nm. Citrate synthase was used as a marker for overall mitochondrial content.
Immunofluorescence staining with antibodies specific for subunits of five respiratory chain complexes was performed at the Molecular Neuropathology Laboratory, Texas Children’s Hospital. All antibodies were obtained from Abcam [Complex I, anti-NDUFS3 (ab110246); Complex II, anti-SDHB (ab14714); Complex III, anti-UQCRC2 (ab14745); Complex IV-I, anti-MTCO-1 (ab14705); Complex IV-IV, anti-COX IV (ab14744); Complex V, anti-OSCP (ab110276); PDH, anti-Pyruvate dehydrogenase E1 component subunit alpha (ab 110334)]. Cryosections of skeletal muscle were processed for immunofluorescence using a previously described protocol  with the above antibodies to respiratory chain enzyme complex proteins (green fluorescence); antibody to porin (Abcam ab14734; red fluorescence) served as reference control for mitochondrial density and distribution. Images were captured using Leica imaging system with Cytovision software. For each complex, fibers with strong red (porin) staining but no green staining were considered totally deficient (i.e. homoplasmic for mutant mitochondria), fibers with a patchy green and red staining were considered partially deficient (i.e. heteroplasmic for mutant mitochondria), while fibers lacking both red and green staining were considered mitochondrially hypodense.
Comprehensive mtDNA analysis by massively parallel (“next generation”) sequencing was performed on the paraspinal muscle and blood according to previously published methods ,. Briefly, the entire mitochondrial genome was amplified using long-range PCR. The PCR products were sequenced to approximately 20,000 depth of coverage using the Illumina Hiseq. 2000, with the Revised Cambridge Reference Sequence (rCRS NC_012920) used as reference. The quantitative measurements of reference base and observed base for a single variant were reported as mean percentage value, with coding region variants reported for heteroplasmy ≥1.5%. Sanger sequencing was performed for sequence confirmation of heteroplasmic findings in the coding region that exceeded 20% heteroplasmy. Massively parallel sequencing of mtDNA followed by Sanger sequencing of the breakpoint (deletion/junction) regions was used for mtDNA deletion analysis, as described previously ,. mtDNA copy number was determined according to published procedures . Finally, nuclear genome regions that include 14 nuclear genes (C10ORF2, DGUOK, MPV17, OPA1, OPA3, POLG, POLG2, RRM2B, SLC25A4, SUCLG1, SUCLG2, TK2, and TYMP) known to be involved in the maintenance of mtDNA integrity and the deoxynucleotide salvage pathway were also analyzed using massively parallel sequencing.
At age 65, the female patient developed progressive scoliosis consisting of decompensated deformity with severe sagittal and coronal plane imbalance that worsened rapidly over the next four years; past medical history was significant for stable scoliosis identified in the late adolescence. The patient also had a history of borderline hypertension and hyperlipidemia with transient ischemic attack (TIA) at age 62; rhytidectomy at age 64; and elbow surgery at age 66. Family history was positive for stable scoliosis in both her mother (who died at age 95) and her son (currently age 37). The patient reported increasing lumbosacral and leg pain as the scoliosis progressed; in addition, she developed mild dysphagia in the year preceding surgery, but has not undergone any additional testing to evaluate this symptom. She has normal stature (164 cm) and has reported no headaches, no myoclonus, no diplopia, no hearing loss, and no exercise intolerance.
Muscle pathology and molecular genetics
Mitochondrial respiratory chain enzyme analysis
Electron transport chain activity assay
Patient (normalized values)
Control (+/– SD) (nmol/min/mg)1
NADH : ferricyanide dehydrogenase
280 +/– 91
I + III
NADH : cytochrome C reductase (total)
28.2 +/– 4.3
NADH : cytochrome C reductase (rotenone sensitive)
9.1 +/– 2.5
II + III
Succinate : cytochrome C reductase
4.9 +/– 1.1
Sytochrome C oxidase
29.2 +/– 9.1
Citrate synthase (mitochondrial content marker)
280 +/– 95
Mitochondrial respiratory chain immunofluorescence analysis
Tissue area showing reduced staining1
Partially or totally deficient fibers2
What is the clinical significance of this novel mtDNA variant, which is not listed as a polymorphism in the Mitomap and mtDB mtDNA databases and was not detected in ~ 5000 individuals whose mtDNA was sequenced by the Baylor Medical Genetics Laboratories? The m.12293G > A mutation changes a G:C pairing to an A:C mispairing in the anticodon stem of MT-TL2 (tRNA LeuCUN); this position is conserved in all organisms examined by Weber et al.  and is adjacent to a similar mutation (m.12294G > A) that causes chronic progressive external ophthalmoplegia (CPEO), a classic mitochondrial disorder . Several other point mutations in the MT-TL2 gene have been implicated in mitochondrial diseases, including CPEO, MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke syndrome), and other mitochondrial myopathies including isolated dilated cardiomyopathy –,,,. The absence of m.12293G > A (MT-TL2) variant in the patient’s blood suggests that this mtDNA variant is a novel point mutation that can lead to an isolated skeletal muscle (in this case paraspinal) myopathy. However, analysis of the patient’s paraspinal muscle mtDNA also showed multiple mtDNA deletions (Figure 4 and Additional file 1: Figure S1) that likely contributed to the mitochondrial myopathy phenotype; thus, studies of cybrids (immortalized cells whose mitochondria have been replaced by mitochondria with the point mutation of interest ) will be required to definitively demonstrate the pathogenicity of the newly identified MT-TL2 mutation.
Interestingly, the patient first developed scoliosis in the late adolescence, but her symptoms remained stable until age 65, when she experienced rapid progression. The family history of scoliosis (the patient’s mother and son also developed scoliosis in the mid-late adolescence) raised the possibility that a maternally-inherited mtDNA mutation was the underlying cause of their spine deformity, as was recently demonstrated for a family with a late-onset axial myopathy due to a mutation in the mitochondrial tRNA Phe gene . However, no mtDNA abnormalities were identified in the patient’s son’s blood (to date, he has not undergone a muscle biopsy). The patient’s mother is deceased and her blood was not available for genetic testing; interestingly, however, her scoliosis remained stable throughout the whole adult life (> seven decades). Thus, it is likely that the patient’s initial scoliosis, which was relatively mild and remained stable for more than four decades, represents a separate familial disorder that still has an unexplained etiology; in contrast, the rapidly-progressive scoliosis the patient developed at the age of 65 is a consequence of the primary axial mitochondrial myopathy caused by the accumulation of somatic mtDNA abnormalities, including multiple mtDNA deletions and m.12293G > A mtDNA mutation. An alternative (but less likely) possibility is that m.12293G > A (MT-TL2) mutation is present in the patient’s blood and other tissues, but is below the current detection limit of the massively parallel sequencing (1% of heteroplasmy); in that scenario, the familial non-progressive scoliosis developed by all three family members would be due to m.12293G > A (MT-TL2) mutation, while the rapid symptom progression experienced only by our patient would be attributed to somatic acquisition of multiple mtDNA deletions. If the patient’s son undergoes a paraspinal muscle biopsy in the future, it may be possible to definitively differentiate between these two scenarios.
Despite obvious morphologic and genetic abnormalities present in the patient’s muscle biopsy, no significant deficiencies of electron transport chain enzymes were detected using standard biochemical assays (Table 1). In contrast, immunofluorescence assays for expression of five respiratory chain complexes showed widespread abnormalities (Figure 3 and Table 2). The discrepancy between the two methods could be due to a difference in sensitivity between imaging assays (which can distinguish affected from non-affected cells) and biochemical assays (which are performed on tissue homogenates). An additional methodological issue is the lack of proper enzyme activity control values for infrequently biopsied tissues (such as the paraspinal muscle): as in our case, a non-significant decrease in the complex I and IV activities was reported in a case of a familial axial myopathy associated with tRNA Phe mutation . Finally, a problem with inter-laboratory reproducibility of mitochondrial respiratory chain biochemical assays has been reported ,. Thus, performing immunofluorescence in parallel with biochemical testing may increase the detection sensitivity for respiratory chain abnormalities, particularly when changes in the mitochondrial enzyme activity approach but do not meet the threshold for statistical significance.
In summary, this case illustrates that mitochondrial myopathy can underlie rapidly-progressive adult-onset scoliosis in the absence of significant chronic myopathic changes and that mitochondrial disorders should be considered in the differential diagnosis of the primary axial myopathy.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We thank Ms. Christine Lin for help with figure preparation.
- Lenoir T, Guedj N, Boulu P, Guigui P, Benoist M: Camptocormia: the bent spine syndrome, an update. Eur Spine J 2010, 19(8):1229–1237. [10.1007/s00586–010–1370–5] 10.1007/s00586-010-1370-5View ArticlePubMedPubMed CentralGoogle Scholar
- Wrede A, Margraf NG, Goebel HH, Deuschl G, Schulz-Schaeffer WJ: Myofibrillar disorganization characterizes myopathy of camptocormia in Parkinson’s disease. Acta Neuropathol 2012, 123(3):419–432. doi:10.1007/s00401–011–0927–7 10.1007/s00401-011-0927-7View ArticlePubMedGoogle Scholar
- Tiple D, Fabbrini G, Colosimo C, Ottaviani D, Camerota F, Defazio G, Berardelli A: Camptocormia in Parkinson disease: an epidemiological and clinical study. J Neurol Neurosurg Psychiatry 2009, 80(2):145–148. doi:10.1136/jnnp.2008.150011 10.1136/jnnp.2008.150011View ArticlePubMedGoogle Scholar
- Gdynia HJ, Sperfeld AD, Unrath A, Ludolph AC, Sabolek M, Storch A, Kassubek J: Histopathological analysis of skeletal muscle in patients with Parkinson’s disease and ´dropped head´/´bent spine´ syndrome. Parkinsonism Relat Disord 2009, 15(9):633–639. doi:10.1016/j.parkreldis.2009.06.003 10.1016/j.parkreldis.2009.06.003View ArticlePubMedGoogle Scholar
- Gomez-Puerta JA, Peris P, Grau JM, Martinez MA, Guanabens N: Camptocormia as a clinical manifestation of mitochondrial myopathy. Clin Rheumatol 2007, 26(6):1017–1019. doi:10.1007/s10067–006–0259–5 10.1007/s10067-006-0259-5View ArticlePubMedGoogle Scholar
- Mahjneh I, Marconi G, Paetau A, Saarinen A, Salmi T, Somer H: Axial myopathy–an unrecognised entity. J Neurol 2002, 249(6):730–734. doi:10.1007/s00415–002–0701–9 10.1007/s00415-002-0701-9View ArticlePubMedGoogle Scholar
- Serratrice G: Axial myopathies: an elderly disorder. Acta myologica 2007, 26(1):11–13.PubMedPubMed CentralGoogle Scholar
- Sakiyama Y, Okamoto Y, Higuchi I, Inamori Y, Sangatsuda Y, Michizono K, Watanabe O, Hatakeyama H, Goto Y, Arimura K, Takashima H: A new phenotype of mitochondrial disease characterized by familial late-onset predominant axial myopathy and encephalopathy. Acta Neuropathol 2011, 121(6):775–783. doi:10.1007/s00401–011–0818-y 10.1007/s00401-011-0818-yView ArticlePubMedPubMed CentralGoogle Scholar
- Kirby DM, Thorburn DR, Turnbull DM, Taylor RW: Biochemical assays of respiratory chain complex activity. Methods Cell Biol 2007, 80: 93–119. doi:10.1016/S0091–679X(06)80004-X 10.1016/S0091-679X(06)80004-XView ArticlePubMedGoogle Scholar
- Trounce IA, Kim YL, Jun AS, Wallace DC: Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol 1996, 264: 484–509. doi:10.1016/S0076–6879(96)64044–0 10.1016/S0076-6879(96)64044-0View ArticlePubMedGoogle Scholar
- Hanson BJ, Capaldi RA, Marusich MF, Sherwood SW: An immunocytochemical approach to detection of mitochondrial disorders. J Histochem Cytochem 2002, 50(10):1281–1288. 10.1177/002215540205001001View ArticlePubMedGoogle Scholar
- Cui H, Li F, Chen D, Wang G, Truong CK, Enns GM, Graham B, Milone M, Landsverk ML, Wang J, Zhang W, Wong LJ: Comprehensive next-generation sequence analyses of the entire mitochondrial genome reveal new insights into the molecular diagnosis of mitochondrial DNA disorders. Genet Med 2013, 15(5):388–394. doi:10.1038/gim.2012.144 10.1038/gim.2012.144View ArticlePubMedGoogle Scholar
- Zhang W, Cui H, Wong LJ: Comprehensive one-step molecular analyses of mitochondrial genome by massively parallel sequencing. Clin Chem 2012, 58(9):1322–1331. doi:10.1373/clinchem.2011.181438 10.1373/clinchem.2011.181438View ArticlePubMedGoogle Scholar
- Dimmock D, Tang LY, Schmitt ES, Wong LJ: Quantitative evaluation of the mitochondrial DNA depletion syndrome. Clin Chem 2010, 56(7):1119–1127. doi:10.1373/clinchem.2009.141549 10.1373/clinchem.2009.141549View ArticlePubMedGoogle Scholar
- Weber K, Wilson JN, Taylor L, Brierley E, Johnson MA, Turnbull DM, Bindoff LA: A new mtDNA mutation showing accumulation with time and restriction to skeletal muscle. Am J Hum Genet 1997, 60(2):373–380.PubMedPubMed CentralGoogle Scholar
- Pulkes T, Liolitsa D, Nelson IP, Hanna MG: Classical mitochondrial phenotypes without mtDNA mutations: the possible role of nuclear genes. Neurology 2003, 61(8):1144–1147. 10.1212/01.WNL.0000090465.27024.3DView ArticlePubMedGoogle Scholar
- Cardaioli E, Da Pozzo P, Radi E, Dotti MT, Federico A: A novel heteroplasmic tRNA(Leu(CUN)) mtDNA point mutation associated with chronic progressive external ophthalmoplegia. Biochem Biophys Res Commun 2005, 327(3):675–678. doi:10.1016/j.bbrc.2004.11.170 10.1016/j.bbrc.2004.11.170View ArticlePubMedGoogle Scholar
- Coku J, Shanske S, Mehrazin M, Tanji K, Naini A, Emmanuele V, Patterson M, Hirano M, DiMauro S: Slowly progressive encephalopathy with hearing loss due to a mutation in the mtDNA tRNA(Leu(CUN)) gene. J Neurol Sci 2010, 290(1-2):166–168. doi:10.1016/j.jns.2009.12.001 10.1016/j.jns.2009.12.001View ArticlePubMedGoogle Scholar
- Fu K, Hartlen R, Johns T, Genge A, Karpati G, Shoubridge EA: A novel heteroplasmic tRNAleu(CUN) mtDNA point mutation in a sporadic patient with mitochondrial encephalomyopathy segregates rapidly in skeletal muscle and suggests an approach to therapy. Hum Mol Genet 1996, 5(11):1835–1840. doi:10.1093/hmg/5.11.1835 10.1093/hmg/5.11.1835View ArticlePubMedGoogle Scholar
- Wang J, Brautbar A, Chan AK, Dzwiniel T, Li FY, Waters PJ, Graham BH, Wong LJ: Two mtDNA mutations 14487 T > C (M63V, ND6) and 12297 T > C (tRNA Leu) in a Leigh syndrome family. Mol Genet Metab 2009, 96(2):59–65. doi:10.1016/j.ymgme.2008.10.006 10.1016/j.ymgme.2008.10.006View ArticlePubMedGoogle Scholar
- Cardaioli E, Da Pozzo P, Malfatti E, Gallus GN, Rubegni A, Malandrini A, Gaudiano C, Guidi L, Serni G, Berti G, Dotti MT, Federico A: Chronic progressive external ophthalmoplegia: a new heteroplasmic tRNA(Leu(CUN)) mutation of mitochondrial DNA. J Neurol Sci 2008, 272(1-2):106–109. doi:10.1016/j.jns.2008.05.005 10.1016/j.jns.2008.05.005View ArticlePubMedGoogle Scholar
- Grasso M, Diegoli M, Brega A, Campana C, Tavazzi L, Arbustini E: The mitochondrial DNA mutation T12297C affects a highly conserved nucleotide of tRNA(Leu(CUN)) and is associated with dilated cardiomyopathy. Eur J Hum Genet 2001, 9(4):311–315. doi:10.1038/sj.ejhg.5200622 10.1038/sj.ejhg.5200622View ArticlePubMedGoogle Scholar
- McFarland R, Elson JL, Taylor RW, Howell N, Turnbull DM: Assigning pathogenicity to mitochondrial tRNA mutations: when “definitely maybe” is not good enough. Trends Genet 2004, 20(12):591–596. doi:10.1016/j.tig.2004.09.014 10.1016/j.tig.2004.09.014View ArticlePubMedGoogle Scholar
- Gellerich FN, Mayr JA, Reuter S, Sperl W, Zierz S: The problem of interlab variation in methods for mitochondrial disease diagnosis: enzymatic measurement of respiratory chain complexes. Mitochondrion 2004, 4(5-6):427–439. doi:10.1016/j.mito.2004.07.007 10.1016/j.mito.2004.07.007View ArticlePubMedGoogle Scholar
- Bernier FP, Boneh A, Dennett X, Chow CW, Cleary MA, Thorburn DR: Diagnostic criteria for respiratory chain disorders in adults and children. Neurology 2002, 59(9):1406–1411. 10.1212/01.WNL.0000033795.17156.00View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.